Atropine Infusion After Atropinization
After achieving atropinization in organophosphate or carbamate poisoning, start a continuous atropine infusion to maintain atropinization. 1
Rationale for Continuous Atropine Infusion
The 2023 AHA guideline explicitly states that "maintenance of atropinization can be achieved by an atropine infusion" 1. This is the definitive recommendation from the highest quality guideline source available.
Why Continuous Infusion Over Bolus Dosing
The evidence strongly favors continuous infusion:
- Reduced mortality: Studies demonstrate mortality reduction from 22.5% with bolus dosing to 8% with incremental boluses followed by continuous infusion 2
- Faster atropinization: Mean time to atropinization drops dramatically from 151.74 minutes with bolus dosing to 23.90 minutes with incremental approach plus infusion 2
- Lower atropine toxicity: Continuous infusion reduces atropine toxicity from 28.4% to 12.0% compared to repeated boluses 2
- Fewer complications: Intermediate syndrome occurs less frequently (4% vs 13.6%), and respiratory support requirements decrease (8% vs 24.7%) 2
Practical Implementation
Initial Atropinization Protocol
- Give 5 mg IV atropine bolus initially
- Follow with 2.5 mg every 5-10 minutes until atropinization achieved 3
- Atropinization endpoints: clear chest on auscultation, heart rate >80/min, systolic BP >80 mmHg 1
Maintenance Infusion
Once atropinized, transition to continuous atropine infusion rather than intermittent boluses. The research shows mean atropine requirements of 735 mg (range 85-3000 mg) over the treatment course, with maximum dosing typically on day 1 3.
Concurrent Pralidoxime (2-PAM) Infusion
Also initiate continuous pralidoxime infusion at 7.5 mg/kg/hour (maximum 500 mg/hour) after a 2g loading dose 3. The AHA guideline gives pralidoxime a Class 2a recommendation for organophosphate poisoning 1. The combination of continuous atropine plus pralidoxime infusion demonstrates:
- Mean 2-PAM infusion duration of 96.4 hours 3
- Improved outcomes with 12.5% mortality in severe cases requiring mechanical ventilation 3
- Shortened cholinesterase reactivation time 4, 5
Critical Caveats
Do not withhold pralidoxime when the poison class is unknown - the guideline explicitly states oximes should not be withheld in cholinesterase poisoning cases where you cannot distinguish organophosphate from carbamate 1.
The continuous infusion approach provides more stable therapeutic levels, reduces the risk of both under-treatment (leading to cholinergic crisis) and over-treatment (causing atropine toxicity), and ultimately improves survival in this life-threatening poisoning scenario.